Literature DB >> 9119648

Acute cardiovascular effects of intravenous cyclosporine.

J F Navarro1, C Mora, R Marcén, J L Teruel, C Gámez, J J Jiménez, L Orofino, J Ortuño.   

Abstract

The acute effects of intravenous (i.v.) cyclosporine A (CsA) on blood pressure and other haemodynamic parameters were examined in 8 patients with end-stage renal disease on haemodialysis (HD). The study was performed after the mid-week haemodialysis session, when the patients were on their dry body weight. Each patient received an i.v. infusion of 5 mg/kg of CsA in 120 ml of 5% dextrose in water during 2 hours. Heart rate, systolic and diastolic blood pressure (SBP, DBP) were monitored by the Holter system. An echocardiogram (M-mode 2-dimensional and Doppler sonography) was performed using an automatic device (Ultramark 6) before CsA administration, at 30, 60 and 120 minutes during CsA infusion, and at 30 minutes thereafter. SBP, DBP and calculated peripheral vascular resistance (CPVR) increased significantly in respect to basal values at 120 and 150 minutes (SBP: basal 130 +/- 21, 120 min: 136 +/- 20, 150 min: 140 +/- 18, p < 0.05 and p < 0.01, respectively. DBP: basal 80 +/- 9, 120 min: 86 +/- 13, 150 min: 88 +/- 13, p < 0.05 and p < 0.01, respectively. CPVR: basal 1000 +/- 228, 120 min: 1178 +/- 305, 150 min: 1236 +/- 270 dyne/s/cm5, p < 0.01). However, systolic volume (SV) and cardiac output (CO) showed significant decreases from the basal values (SV: basal 103 +/- 29, 120 min: 85 +/- 22, 150 min: 85 +/- 17, p < 0.05. CO: basal 8.2 +/- 2, 120 min: 7.3 +/- 1.1, 150 min: 7 +/- 1.2 l/min, p < 0.05). In conclusion, CsA infusion produces a significant elevation of blood pressure, which seems to be mediated by a direct action on peripheral vascular resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9119648     DOI: 10.1007/bf02550970

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  14 in total

1.  Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.

Authors:  G Feutren; M J Mihatsch
Journal:  N Engl J Med       Date:  1992-06-18       Impact factor: 91.245

2.  Cyclosporine-induced hypertension in sheep. The role of thromboxanes.

Authors:  J J Tresham; J A Whitworth; B A Scoggins; W M Bennett
Journal:  Transplantation       Date:  1990-01       Impact factor: 4.939

3.  Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.

Authors:  D J Sahn; A DeMaria; J Kisslo; A Weyman
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

4.  Prevention of acute cyclosporine-induced renal blood flow inhibition and improved immunosuppression with verapamil.

Authors:  I Dawidson; P Rooth; W R Fry; Z Sandor; C Willms; L Coorpender; C Alway; J Reisch
Journal:  Transplantation       Date:  1989-10       Impact factor: 4.939

5.  Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent.

Authors:  J J Curtis; R G Luke; P Jones; A G Diethelm
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

6.  Cyclosporine-induced sympathetic activation and hypertension after heart transplantation.

Authors:  U Scherrer; S F Vissing; B J Morgan; J A Rollins; R S Tindall; S Ring; P Hanson; P K Mohanty; R G Victor
Journal:  N Engl J Med       Date:  1990-09-13       Impact factor: 91.245

7.  Suppression of plasma renin activity by cyclosporine.

Authors:  J P Bantle; R J Boudreau; T F Ferris
Journal:  Am J Med       Date:  1987-07       Impact factor: 4.965

8.  Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial.

Authors:  C N Ellis; M S Fradin; J M Messana; M D Brown; M T Siegel; A H Hartley; L L Rocher; S Wheeler; T A Hamilton; T G Parish
Journal:  N Engl J Med       Date:  1991-01-31       Impact factor: 91.245

9.  Cyclosporine-induced renal dysfunction in human renal allograft recipients.

Authors:  B A Kiberd
Journal:  Transplantation       Date:  1989-12       Impact factor: 4.939

10.  Cyclosporin in therapeutic doses increases renal allograft vascular resistance.

Authors:  J J Curtis; R G Luke; E Dubovsky; A G Diethelm; J D Whelchel; P Jones
Journal:  Lancet       Date:  1986-08-30       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.